Chronic Treatment with Carvedilol Improves Ventricular Function and Reduces Myocyte Apoptosis in an Animal Model of Heart Failure

View/ Open
Author
Okafor, Chukwuka C
Perreault-Micale, Cynthia
Hajjar, Roger J
Lebeche, Djamel
Skiroman, Klara
Jabbour, George
Doye, Angelia A
Lee, Michael X.
Laste, Nancy
Published Version
https://doi.org/10.1186/1472-6793-3-6Metadata
Show full item recordCitation
Okafor, Chukwuka C., Cynthia Perreault-Micale, Roger J. Hajjar, Djamel Lebeche, Klara Skiroman, George Jabbour, Angelia A. Doye, Michael X. Lee, Nancy Laste, and Judith K. Gwathmey. 2003. Chronic treatment with Carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. BMC Physiology 3:6.Abstract
Background: \(\beta\)-blocker treatment has emerged as an effective treatment modality for heart failure. Interestingly, \(\beta\)-blockers can activate both pro-apoptotic and anti-apoptotic pathways. Nevertheless, the mechanism for improved cardiac function seen with \(\beta\)-blocker treatment remains largely unknown. Carvedilol is a non-selective \(\beta\)-blocker with \(\alpha\)-receptor blockade and antioxidant properties. We therefore studied the impact of the effects of carvedilol in an animal model of end-stage heart failure. Results: To test whether chronic treatment with \(\beta\)-blockade decreases apoptosis, we treated myopathic turkeys with two dosages of carvedilol, 1 mg/kg (\(DCM_1\)) and 20 mg/kg (\(DCM_{20}\)), for four weeks and compared them to non-treated DCM animals (\(DCM_0\)) and to control turkeys (CON). Echocardiographic measurements showed that non-treated DCM animals had a significantly lower fractional shortening (FS) when compared to CON (68.73 \(\pm\) 1.37 vs. 18.76 \(\pm\) 0.59%, p < 0.001). Both doses of carvedilol significantly improved FS (33.83 \(\pm\) 10.11 and 27.73 \(\pm\) 6.18% vs. 18.76 \(\pm\) 0.59 % for untreated DCM, p < 0.001). DCM left ventricles were characterized by a higher percentage of apoptotic nuclei when compared to CON (5.64 \(\pm\) 0.49 vs. 1.72 \(\pm\) 0.12%, respectively p < 0.001). Both doses of carvedilol significantly reduced the number of apoptotic nuclei (2.32 \(\pm\) 0.23% and 2.36 \(\pm\) 0.26% 1 mg and 20 mg/kg respectively). Conclusions: Carvedilol improves ventricular function. Furthermore, treatment with carvedilol decreased the incidence of apoptosis in cardiac myocytes from failing hearts at both doses. These data suggest that the inhibition of apoptosis with carvedilol may lead to improvement in ventricular function and may underlie a beneficial effect of \(\beta\)-blockade independent of heart rate lowering effects.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC212709/pdf/http://www.biomedcentral.com/1472-6793/3/6
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10219388
Collections
- HMS Scholarly Articles [17852]
Contact administrator regarding this item (to report mistakes or request changes)